Share

Onconic Therapeutics

18360

Last Updated 16.10.2025

Issuer Rating

2/7

Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

₩ 151.49M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks

18360

Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Onconic Therapeutics, Inc. is a biopharmaceutical company. It engages in the research and development of new drugs in the field of acid-related diseases and anti cancer. The company was founded on May 7, 2020 and is headquartered in Seoul, South Korea.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very unfavourable
1/7
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks